Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21153200 | 0.86 | TAAR1 (0.42) | KDM4EMAOBMAOAPOLBRAB9A | |
| SCHEMBL21153210 | 0.86 | TAAR1 (0.42) | KDM4EMAOBMAOAPOLBRAB9A | |
| SCHEMBL7800224 | 0.84 | SIGMAR1 (0.53) | MAOBPOLBLMNASIGMAR1IDO1 | |
| SCHEMBL26858667 | 0.82 | CYP2D6 (0.43) | KDM4ELMNASIGMAR1IDO1 | |
| SCHEMBL13900689 | 0.81 | SLC1A1 (0.44) | SLC1A1MAOBMAOAIDO1AGXT | |
| SCHEMBL21153204 | 0.79 | CASR (0.56) | KDM4EMAOBPOLBIDO1AGXT | |
| SCHEMBL23032999 | 0.77 | SIGMAR1 (0.69) | SLC1A1POLBLMNASIGMAR1 | |
| SCHEMBL22192859 | 0.75 | MAOB (0.33) | SLC1A1KDM4EMAOBMAOASCN9A | |
| SCHEMBL25208573 | 0.74 | MEN1 (0.53) | KDM4ERAB9A | |
| SCHEMBL3211882 | 0.71 | SLC1A1 (0.54) | SLC1A1MAOBIDO1AGXTPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827582-B2 | Substituted amines as disrupters of ABETA42 oligomer formation | ACELOT, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | ACELOT,INC (US) | 2021-02-25 | — | — | US | disclosed |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | ACELOT, INC. | 2020-07-16 | — | — | US | disclosed |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | ACELOT, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | ACELOT, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | APP, PSEN2, PSEN1 | SLC1A1 2068/4885KDM4E 4863/4885MAOB 927/4885 |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | APP, PSEN2, PSEN1 | SLC1A1 1919/4885KDM4E 4816/4885MAOB 615/4885 |
| US-11827582-B2 | Substituted amines as disrupters of ABETA42 oligomer formation | APP, PSEN2, BACE1 | SLC1A1 1396/4885KDM4E 4220/4885MAOB 62/4885 |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | APP, PSEN2, PSEN1 | SLC1A1 2068/4885KDM4E 4863/4885MAOB 927/4885 |
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | HTT, TARDBP, SNCA | SLC1A1 2373/4885KDM4E 4369/4885MAOB 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.